114 related articles for article (PubMed ID: 38307818)
1. The Effect of Treatment Intensification on Other-Cause Mortality in Clear-Cell Metastatic Renal Cell Carcinoma Patients.
Incesu RB; Barletta F; Garcia CC; Scheipner L; Morra S; Baudo A; Assad A; Tian Z; Saad F; Shariat SF; Carmignani L; Longo N; Ahyai S; Chun FKH; Briganti A; Tilki D; Graefen M; Karakiewicz PI
Clin Genitourin Cancer; 2024 Apr; 22(2):420-425. PubMed ID: 38307818
[TBL] [Abstract][Full Text] [Related]
2. Differences in Survival of Clear Cell Metastatic Renal Cell Carcinoma According to Partial vs. Radical Cytoreductive Nephrectomy.
Cano Garcia C; Flammia RS; Piccinelli M; Panunzio A; Tappero S; Barletta F; Incesu RB; Law KW; Morra S; Tian Z; Saad F; Kapoor A; Shariat SF; Longo N; Tilki D; Briganti A; Terrone C; Antonelli A; De Cobelli O; Hoeh B; Kluth LA; Chun FKH; Karakiewicz PI
Clin Genitourin Cancer; 2024 Feb; 22(1):1-6. PubMed ID: 37344282
[TBL] [Abstract][Full Text] [Related]
3. The Association Between Cytoreductive Nephrectomy and Overall Survival in Metastatic Renal Cell Carcinoma with Primary Tumor Size ≤4 cm.
Tappero S; Barletta F; Piccinelli ML; Cano Garcia C; Incesu RB; Morra S; Scheipner L; Tian Z; Parodi S; Dell'Oglio P; Palumbo C; Briganti A; De Cobelli O; Chun FKH; Graefen M; Longo N; Ahyai S; Saad F; Shariat SF; Suardi N; Borghesi M; Terrone C; Karakiewicz PI
Eur Urol Focus; 2023 Sep; 9(5):742-750. PubMed ID: 36906483
[TBL] [Abstract][Full Text] [Related]
4. Survival after Cytoreductive Nephrectomy in Metastatic Non-clear Cell Renal Cell Carcinoma Patients: A Population-based Study.
Marchioni M; Bandini M; Preisser F; Tian Z; Kapoor A; Cindolo L; Primiceri G; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Eur Urol Focus; 2019 May; 5(3):488-496. PubMed ID: 29229582
[TBL] [Abstract][Full Text] [Related]
5. Effect of African-American race on cancer specific mortality differs according to clear cell vs. non-clear cell histologic subtype in metastatic renal cell carcinoma.
Marchioni M; Harmouch SS; Nazzani S; Bandini M; Preisser F; Tian Z; Kapoor A; Cindolo L; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Cancer Epidemiol; 2018 Jun; 54():112-118. PubMed ID: 29715680
[TBL] [Abstract][Full Text] [Related]
6. Other-cause mortality and access to care in metastatic renal cell carcinoma according to race/ethnicity.
Sorce G; Hoeh B; Hohenhorst L; Panunzio A; Tappero S; Tian Z; Larcher A; Capitanio U; Tilki D; Terrone C; Chun FKH; Antonelli A; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
Urol Oncol; 2022 Nov; 40(11):493.e9-493.e16. PubMed ID: 35907705
[TBL] [Abstract][Full Text] [Related]
7. Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non-clear Cell Renal Cell Carcinoma Patients.
Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Mistretta FA; Tian Z; Musi G; Montanari E; Soulières D; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
Eur Urol Focus; 2021 May; 7(3):598-607. PubMed ID: 32444303
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years.
Marchioni M; Preisser F; Bandini M; Nazzani S; Tian Z; Kapoor A; Cindolo L; Abdollah F; Tilki D; Briganti A; Montorsi F; Shariat SF; Schips L; Karakiewicz PI
Eur Urol Focus; 2019 May; 5(3):467-473. PubMed ID: 29398456
[TBL] [Abstract][Full Text] [Related]
9. Mortality According to Treatment in Metastatic Collecting Duct Renal Cell Carcinoma.
Panunzio A; Sorce G; Tappero S; Hohenhorst L; Cano Garcia C; Piccinelli M; Tian Z; Tafuri A; De Cobelli O; Chun FKH; Tilki D; Terrone C; Briganti A; Kapoor A; Saad F; Shariat SF; Cerruto MA; Antonelli A; Karakiewicz PI
Clin Genitourin Cancer; 2023 Apr; 21(2):295-300. PubMed ID: 36117092
[TBL] [Abstract][Full Text] [Related]
10. Cancer-specific Mortality in T1a Renal Cell Carcinoma Treated with Local Tumor Destruction Versus Partial Nephrectomy.
Sorce G; Hoeh B; Hohenhorst L; Panunzio A; Tappero S; Tian Z; Kokorovic A; Larcher A; Capitanio U; Tilki D; Terrone C; Chun FKH; Antonelli A; Saad F; Shariat SF; Montorsi F; Briganti A; Karakiewicz PI
Eur Urol Focus; 2023 Jan; 9(1):125-132. PubMed ID: 35918270
[TBL] [Abstract][Full Text] [Related]
11. A non-cancer-related survival benefit is associated with partial nephrectomy.
Sun M; Trinh QD; Bianchi M; Hansen J; Hanna N; Abdollah F; Shariat SF; Briganti A; Montorsi F; Perrotte P; Karakiewicz PI
Eur Urol; 2012 Apr; 61(4):725-31. PubMed ID: 22172373
[TBL] [Abstract][Full Text] [Related]
12. Survival of metastatic renal cell carcinoma patients continues to improve over time, even in targeted therapy era.
Marchioni M; Bandini M; Pompe RS; Tian Z; Martel T; Kapoor A; Cindolo L; Berardinelli F; Briganti A; Shariat SF; Schips L; Karakiewicz PI
Int Urol Nephrol; 2017 Dec; 49(12):2143-2149. PubMed ID: 28932952
[TBL] [Abstract][Full Text] [Related]
13. Partial nephrectomy seems to confer a survival benefit relative to radical nephrectomy in metastatic renal cell carcinoma.
Mazzone E; Nazzani S; Preisser F; Tian Z; Marchioni M; Bandini M; Capitanio U; Kapoor A; Tilki D; Montorsi F; Shariat SF; Saad F; Briganti A; I Karakiewicz P
Cancer Epidemiol; 2018 Oct; 56():118-125. PubMed ID: 30173050
[TBL] [Abstract][Full Text] [Related]
14. Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities.
Luzzago S; Palumbo C; Rosiello G; Knipper S; Pecoraro A; Nazzani S; Tian Z; Musi G; Montanari E; Shariat SF; Saad F; Briganti A; de Cobelli O; Karakiewicz PI
Cancer Causes Control; 2020 Mar; 31(3):263-272. PubMed ID: 31993859
[TBL] [Abstract][Full Text] [Related]
15. Contemporary Cytoreductive Nephrectomy Provides Survival Benefit in Clear-cell Metastatic Renal Cell Carcinoma.
Palumbo C; Mistretta FA; Knipper S; Pecoraro A; Tian Z; Dzyuba-Negrean C; Shariat SF; Saad F; Simeone C; Berruti A; Briganti A; Kapoor A; Antonelli A; Karakiewicz PI
Clin Genitourin Cancer; 2020 Dec; 18(6):e730-e738. PubMed ID: 32800473
[TBL] [Abstract][Full Text] [Related]
16. Cancer-specific mortality in non-metastatic T1a renal cell carcinoma treated with radiotherapy versus partial nephrectomy.
de Angelis M; Morra S; Scheipner L; Siech C; Jannello LMI; Baudo A; Goyal JA; Tian Z; Longo N; Ahyai S; de Cobelli O; Chun FKH; Saad F; Shariat SF; Carmignani L; Montorsi F; Briganti A; Karakiewicz PI
World J Urol; 2024 Mar; 42(1):193. PubMed ID: 38530480
[TBL] [Abstract][Full Text] [Related]
17. Cytoreductive nephrectomy in patients with metastatic non-clear-cell renal cell carcinoma (RCC).
Aizer AA; Urun Y; McKay RR; Kibel AS; Nguyen PL; Choueiri TK
BJU Int; 2014 May; 113(5b):E67-74. PubMed ID: 24053727
[TBL] [Abstract][Full Text] [Related]
18. A population-based comparison of cancer-control rates between radical and partial nephrectomy for T1A renal cell carcinoma.
Crépel M; Jeldres C; Sun M; Lughezzani G; Isbarn H; Alasker A; Capitanio U; Shariat SF; Arjane P; Widmer H; Graefen M; Montorsi F; Perrotte P; Karakiewicz PI
Urology; 2010 Oct; 76(4):883-8. PubMed ID: 20932408
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Significance of Radiographic Lymph Node Invasion in Contemporary Metastatic Renal Cell Carcinoma Patients.
Scheipner L; Incesu RB; Morra S; Baudo A; Assad A; Jannello LMI; Siech C; de Angelis M; Tian Z; Saad F; Shariat SF; Briganti A; Chun FKH; Tilki D; Longo N; Carmignani L; De Cobelli O; Pichler M; Ahyai S; Karakiewicz PI
Clin Genitourin Cancer; 2024 Apr; 22(2):164-170. PubMed ID: 37981546
[TBL] [Abstract][Full Text] [Related]
20. A population-based competing-risks analysis of survival after nephrectomy for renal cell carcinoma.
Bianchi M; Gandaglia G; Trinh QD; Hansen J; Becker A; Abdollah F; Tian Z; Lughezzani G; Roghmann F; Briganti A; Montorsi F; Karakiewicz PI; Sun M
Urol Oncol; 2014 Jan; 32(1):46.e1-7. PubMed ID: 24054864
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
